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Abstract 
 
We assessed the effects of Chinese herbs on the uncomplicated urinary tract infections (UTIs) in women caused by 
fluoroquinolone-resistant strains. A total of 56 pre-menopausal women with uncomplicated UTIs caused by 
fluoroquinolone-resistant strains were included. Urine cultures were carried out. All organisms were proved to be 
fluoroquinolone-resistant at baseline. The patients were orally administrated Chinese herbal concoction for ten days.  
Chinese herbal concoction eradicated the primary pathogen in 71.4% of the patients at the 1-week follow-up. Among the 20 
patients who had bacteriologic failures in the Day 5 of treatment, 2 developed superinfection. Of the failures in the group, 
Proteus mirabilis, Staphylococcus epidermidis and Providencia rettgeri were implicated in 50.0%, 50.0% and 100.0% of the 
failures, respectively. The clinical outcomes were also good, with cure or improvement for more than 80% of all subjects. 
About 14% of the study subjects reported at least one potential adverse event. The adverse events most frequently reported 
were nausea and diarrhea. All patients tolerated the symptoms. The adverse reactions did not prevail after discontinuation of 
the medication. Chinese herbal therapy may be an acceptable alternative for the treatment of uncomplicated UTIs caused by 
fluoroquinolone-resistant uropathogens.  
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Introduction 
 
Uncomplicated urinary tract infections (UTIs) were among the most common bacterial infections seen in general 
practice in women (Jancel et al.,2002; Huang et al.,2002). Of women between ages 20 and 40 years, 25% to 35% had a UTI 
(Foxman et al.,2000). Unfortunately, drug resistance among uropathogens increased steadily during the past several decades, 
resulting in more complex treatment choices. An investigation from Seattle that used administrative data to retrospectively 
identify patients with uncomplicated UTIs found that trimethoprim- sulfamethoxazole resistance increased from 8% in 1992 
to 16% in 1996 (Gupta et al.,1999). In Michigan, a prospective surveillance of drug resistance among pathogens that caused 
uncomplicated UTIs found that trimethoprim-sulfamethoxazole resistance increased from 8% in 1992-1993 to 16% in 
1998-1999 (Brown et al.,2002). Moreover, in the past few years, fluoroquinolones were prescribed more frequently for the 
treatment of such infections. This was followed by an increase in fluoroquinolone-resistant uropathogen infections 
(Kahlmeter,2000; Gales et al.,2000). Currently, the prevalence of fluoroquinolone-resistant isolates of uropathogens was 
reported to be increasing over time in some centers in the United States and Canada (Diekema et al.,2004; Viray et al.,2005; 
Lautenbach et al.,2004; Zhanel et al.,2005), and resistance rates were shown to vary markedly by center, with some hospital 
laboratories reporting >25% of their uropathogens isolates as fluoroquinolone resistant (Diekema et al.,2004; Viray et 
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al.,2005).  
Chinese herbal medicine was an integral part of Traditional Chinese Medicine (TCM) for more than 2000 years. 
Many herbal formulations were developed and used in the treatment of UTI. In our preliminary study, favorable results were 
obtained in UTI patients administered some Chinese herbs. For an alternative therapeutic solution, we conducted a treatment 
trial to assess the effects of Chinese herbs on the uncomplicated UTIs in women caused by fluoroquinolone-resistant strains.  
 
 
Materials and Methods 
Patients 
 
      A total of 56 adult patients from the outpatient clinics of the The First Affilliated Hospital to Changchun University 
of Chinese Medicine with normal renal function (serum creatinine, ≤1.5 mg/dl) and symptomatic uncomplicated lower UTI 
were included in this study. The patients were 20 to 45 years old (mean, 32 years) without significant underlying diseases. 
Among the group, all patients were ambulatory pre-menopausal women. The hospital’s investigational review board 
approved the study. Written informed consent was obtained from the patients at initial enrollment. 
 
Preliminary Evaluation 
 
      The diagnosis of uncomplicated lower UTI was based on the following criteria: significant bacteriuria, determined 
by urine culture and defined as at least 105 colony-forming units of an identified single uropathogen per millilitre of urine, 
accompanied by at least 1 of 6 possible symptoms (dysuria, frequency, urgency, suprapubic pain, burning on micturition, or 
onset or aggravation of urinary incontinence). Urine specimens were obtained by midstream collection or catheterization. 
Urine cultures were carried out at baseline, day 5 of treatment, the last day (day 10) of treatment, and 1 week after treatment. 
All isolated uropathogens were tested for susceptibility to ciprofloxacin, fosfomycin and nitrofurantoin, by using NCCLS 
guidelines. All organisms were proved to be fluoroquinolone-resistant at baseline. 
       The following patients were excluded from the study: patients under age 16 years; patients with upper UTI; 
patients with indwelling catheters; patients with structural abnormalities of the genitourinary tract; patients already receiving 
antimicrobial or antiseptic therapy for UTI; patients with acute toxic conditions, had temperatures greater than 38℃; patients 
with radiographically proven obstructive uropathy; patients with a history of diabetes mellitus; patients with creatinine, serum 
glutamic oxaloacetic transaminase (SGOT), or alkaline phosphatase levels 50% greater than the upper limit of normal for the 
investigator’s laboratory. A special effort was made to exclude pregnant and breast-feeding women. Informed consent was 
obtained from each volunteer. 
 
Treatment 
 
      As an alternative therapeutic method, the patients were orally administrated Chinese herbal concoction. The 
prescription was as follow: Tong Cao [Stachyurus himalaicus Hook.f.et Thoms] 20g, Hua Shi [Talcum] 15g, Chi Shao 
[Paeonia lactiflora Pall.] 15g, Hui Xiang [Foeniculum  vulgare  Mill.] 15g, Guan Gui [Cinnamomum cassia Presl] 15g, Li 
Zhihe [Litchi chinensis Sonn] 15g, Tian Kuizi [Semiaquilegia adoxoides (DC.) makino] 15g, Zihua Diding [Viola ycdoensis 
Mak.] 20g, Ju Mai [Dianthus superbus L.] 15g, Ma Chixian [Portulaca oleracea L] 50g, Pu Gongying [Herba taraxaci] 30g. 
The concoction was prepared by mixing the crude drugs in 800ml water, getting 200ml liquor after the drugs decocted in 
800ml water (100℃ for 30 minutes twice). After cooling, concoction was stored with temperature 18-24℃, humidity 
55%-70%. The concoction was orally administrated by 200ml/day for ten days. 
 
Follow-up Studies 
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     Patients were instructed to return at day 5-10-17 of a 10 day treatment course. At each return visit, a clean-voided 
midstream urine sample was procured for a qualitative and quantitative analysis. During and after treatment, any negative 
urine colony culture was confirmed by a second culture. 
      Laboratory tests that had been performed at baseline [complete blood cell count; SGOT, serum glutamic pyruvic 
transaminase (SGPT), alkaline phosphatase, and serum creatinine determinations] were repeated at the last day of treatment. 
The investigators recorded any new symptoms, physical findings, or laboratory abnormalities.  
        Clinical outcomes were identified at the last day of treatment and 1 week after treatment as cure, improvement, 
failure, unevaluable and unknown. Cure, the absence of all baseline UTI signs and symptoms; Improvement, a decrease in 
severity from the baseline of at least one sign or symptom with no deterioration in any other; Success, either cure or 
improvement; Failure, a worsening of at least one sign or symptom or no change in any signs or symptoms; Unevaluable, no 
pretherapy evaluation of UTI signs and symptoms; Unknown, no clinical evaluation of signs and symptoms was available 
posttreatment. 
 
Bacteriologic Studies 
 
       Urine samples were plated initially on blood agar plates and were quantitated by pour plates or calibrated wire loops. 
Cultures were observed for growth for 48 hours. All bacterial isolates were identified by standard procedures (Edwards et 
al.,1955).The following standards were used: Cure, negative culture at 1 week after treatment; Persistence, ≥105 colonies of 
the original organism per ml during treatment; Relapse, negative culture during therapy and ≥105 colonies of the original 
organism per ml at followup; Reinfection, ≥105 colonies of an organism different from the original organism per ml at 
follow-up; Superinfection, ≥105 colonies of an organism different from the original organism per ml during treatment. This 
assessment was based on routine bacteriological identification of the microorganisms since serotyping was not done. 
 
Statistical analysis 
 
     Paired t test was used for comparison between values before and after treatment. All analyses were carried out using 
SAS version 8.02 (SAS Institute, Cary, NC). P<0.05 was considered statistically significant. 
 
 
Results 
Organisms isolated 
 
     Of the 56 patients in this study, causative organisms isolated from urine cultures before treatment were (with number 
of strains in parentheses): Escherichia coli (35), Pseudomonas aeruginosa (10), Klebsiella pneumoniae (5), Proteus mirabilis 
(2), Staphylococcus epidermidis (2), and one each for Staphylococcus aureus, Proteus morganii, Enterobacter aerogenes, and 
Providencia rettgeri. Two patients were infected with two organisms. 
 
Bacteriologic efficacies 
 
    Table 1 showed the bacteriological results of treatment in 56 patients. Chinese herbal concoction eradicated the 
primary pathogen in 71.4% of the patients at the 1-week follow-up. 
    The isolated causative organisms were listed in Table 2, subclassified by bacteriologic response. Among the 20 
patients who had bacteriologic failures in the Day 5 of treatment, 2 developed superinfection. Of the failures in the group, 
Proteus mirabilis, Staphylococcus epidermidis and Providencia rettgeri were implicated in 50.0%, 50.0% and 100.0% (6 of 
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13) of the failures, respectively. 
 
Clinical outcome 
 
Table 1: Results of treatment in 56 patients. 
No. of patients with: 
Time of assessment Negative 
culture 
Relapse or 
Persistence 
Reinfection or 
superinfection 
Day 5 of treatment 
Last day of treatment 
1-week follow-up 
36 (64.3) * a 
43 (76.8) b 
40 (71.4) b 
20 (35.7) 
11 (19.6) 
14 (25.0) Δ 
0 
2 (3.6) 
2 (3.6) ※ 
*Number in parentheses is percentage of total. 
ΔThe microorganisms responsible for relapse or persistence were: Escherichia coli (7), Pseudomonas aeruginosa (2), 
Klebsiella pneumoniae, Proteus mirabilis and Staphylococcus epidermidis, one each. 
※The microorganisms responsible for reinfection or superinfection were: Staphylococcus aureus, and Candida albicans. 
a p<0.05 versus Baseline. 
b p<0.01 versus Baseline. 
 
Table 2: Bacteriologic response subclassified by etiology 
% of patients 
Day 5 of treatment Last day of treatment 1-week follow-up Organism 
No. of 
patients 
Eradication Persistence Eradication Persistence Eradication Persistence 
Escherichia coli 
Pseudomonas aeruginosa 
Klebsiella pneumoniae 
Proteus mirabilis 
Staphylococcus epidermidis 
Staphylococcus aureus 
Proteus morganii 
Enterobacter aerogenes 
Providencia rettgeri 
35 
10 
5 
2 
2 
1 
1 
1 
1 
71.4 
70.0 
60.0 
50.0 
0 
100.0 
100.0 
0 
0 
28.6 
30.0 
40.0 
50.0 
100.0 
0 
0 
100.0 
100.0 
91.4 
70.0 
60.0 
50.0 
50.0 
100.0 
100.0 
100.0 
0 
8.6 
30.0 
40.0 
50.0 
50.0 
0 
0 
0 
100.0 
85.7 
60.0 
60.0 
50.0 
50.0 
100.0 
100.0 
100.0 
0 
14.3 
40.0 
40.0 
50.0 
50.0 
0 
0 
0 
100.0 
The clinical outcomes for study subjects were also good, with cure or improvement for more than 80% of all subjects at the 
last day of treatment and more than 70% of all subjects in all analyses at 1 week after treatment (Table 3). 
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Table 3: Clinical outcomes of treatment 
 No. of success (%) No. of failure (%) 
The last day of treatment 47 (83.9) a 9 (16.1) 
1 week after treatment 41 (73.2) a 15 (26.8) 
a p<0.01 versus Baseline. 
Adverse Reactions 
 
      Table 4 described the adverse clinical signs, symptoms and laboratory values attributed to the program of treatment 
by the individual investigators. At the last day of treatment, about fourteen percent of the study subjects who received 
Chinese herbal concoction reported at least one potential adverse event. Neither life-threatening reactions nor death was 
ascribed to the therapy. No clinically significant changes in hematologic or biochemical laboratory parameters were identified 
in laboratory monitoring. The adverse events most frequently reported were nausea (7.1% of the patients) and diarrhea (3.6% 
of the patients). All patients tolerated the symptoms and completed the full course of therapy. Progressive abnormalities on 
these adverse reactions did not prevail after discontinuation of the medication.  
Table 4: Number of patients with adverse reactions at the last day of treatment 
Signs and symptoms Number Abnormal laboratory values Number 
Skin Rash 
Nausea 
Diarrhea 
Constipation 
1 
4 
2 
1 
SGOT 
SGPT 
Creatinine 
Red blood cell 
0 
0 
0 
0 
 
 
Discussion 
 
       Since their introduction in the 1980s, fluoroquinolones were used extensively due to their broad antimicrobial 
spectrum, availability in both oral and parenteral formulations, and low toxicity profile. Fluoroquinolones became the 
firstline treatment for UTIs in many areas where resistance to trimethoprim-sulfamethoxazole was prevalent (Warren et al., 
1999). Since then, large surveillance studies of clinical isolates in North America and Europe detected fluoroquinolone 
resistance in a wide range of isolates (Jones et al., 2002; Sahm et al., 2001). 
       A variety of mechanisms might lead to fluoroquinolone resistance; these included target modification of the DNA 
gyrase and topoisomerases and decreased drug concentrations within bacteria mediated by efflux pumps and a loss of porins. 
Organisms were believed to require several mutational events to develop resistance to fluoroquinolones (Hooper et al.,2001). 
Although it was possible to select fluoroquinolone-resistant isolates by performing serial passages in the presence of 
subinhibitory concentrations of various fluoroquinolones (Gilbert et al.,2001), it was considered relatively difficult (Smith, 
1986). In contrast to these laboratory observations, it was believed that resistance to fluoroquinolones emerged often in 
clinical isolates. 
      Some Chinese herbs in the study were proved to have antibacterial activity (Tong et al.,2006). These properties had 
prompted their compound prescription use in the management of UTI. With that in mind, we analyzed the effects of these 
Chinese herbs on the uncomplicated UTIs caused by fluoroquinolone-resistant strains in women. 
     In this study, the subjects were relatively young, with a median age of only 32 years. Escherichia coli was the 
principal infecting organism, and Pseudomonas aeruginosa was the second most frequent. 
     Assessment of treatment outcome in antibiotic trials of UTIs had long been problematic. Inconsistent definitions of 
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clinical cure, differing criteria for bacteriologic cure, and the subjective all-encompassing criterion of investigator assessment 
prevented a rigorous conclusion of published studies. We used two criteria in time: clinical and bacteriologic response. The 
clinical response, judged by patients’ signs and symptoms, was quiet good, with cure or improvement for more than 70% of 
all subjects in all analyses at 1 week after treatment (Table 3). 
     The therapeutic results of Chinese herbs were expected to be poor in the patients wih infections previously. Yet these 
Chinese herbs eradicated most of the primary pathogens from the urine, and a cure rate of 71.4% at the 1-week-follow-up 
was accomplished. The data from this study showed that Chinese herbal concoction was effective in its ability to eradicate 
chronic baeteriuria, the only valid criterion for successful treatment. 
 The tolerance and safety of Chinese herbal concoction were considered excellent in this preliminary trial with only mild 
adverse clinical symptoms occurred which disappeared after discontinuation of the medication. Moreover, no subjects were 
lost to follow-up. 
      Even if a treatment was efficacious, it might not be possible to determine the mechanism of action and the active 
substances immediately, particularly in herbal treatments that contained many compounds. One had to expect the possibility 
that some chemical interactions took place among natural constituents existing in the component herbs of the formula during 
decoction. Decoction might change the extraction rates of the active ingredients and/or produced new artificial substances, 
which might then exhibit new pharmacological activities. However, a mixture of several crude extracts could have greater 
beneficial effects compared with a single plant extract while properly used. First, crude herbs given in combination could act 
synergistically. Second, they could have unknown interactions but could interact to diminish possible adverse side effects of 
one or more of the components. Finally, their combination could prevent the gradual decline in effectiveness observed when 
single herbs were given over long periods of time (Matsuo et al.,1994). 
        The design of our study had some shortcomings. A randomized-controlled double-blind trial would have been ideal 
but was not deemed feasible in this study given the oral route of administration for Chinese herbal concoction. Obviously this 
initial limited therapeutic trial must be extended to a larger group of patients and included long-term follow-up evaluations 
before a definite conclusion could be drawn. In spite of these limitations, it appeared that Chinese herbal therapy might be an 
acceptable alternative for the treatment of uncomplicated UTIs caused by fluoroquinolone-resistant uropathogens. 
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